These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9354692)

  • 1. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
    Verdonck LF; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK
    Blood; 1997 Nov; 90(10):4201-5. PubMed ID: 9354692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
    Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
    Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
    Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
    Moreau P; Méchinaud F; Mahé B; Le Tortorec S; Rapp MJ; Maisonneuve H; Harousseau JL; Milpied N
    Bone Marrow Transplant; 1996 Sep; 18(3):665-7. PubMed ID: 8879639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience.
    Verdonck LF
    Leuk Lymphoma; 1999 Jun; 34(1-2):129-36. PubMed ID: 10350340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.
    Ratanatharathorn V; Uberti J; Karanes C; Abella E; Lum LG; Momin F; Cummings G; Sensenbrenner LL
    Blood; 1994 Aug; 84(4):1050-5. PubMed ID: 8049425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
    Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation.
    Vaishampayan U; Karanes C; Du W; Varterasian M; al-Katib A
    Cancer Invest; 2002; 20(3):303-10. PubMed ID: 12025224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
    Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
    Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
    Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
    Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma.
    Mandigers CM; Raemaekers JM; Schattenberg AV; Roovers EA; Bogman MJ; van der Maazen RW; De Pauw BE; De Witte T
    Br J Haematol; 1998 Jan; 100(1):198-206. PubMed ID: 9450812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
    van Besien KW; Khouri IF; Giralt SA; McCarthy P; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Bellare N; Nath R
    J Clin Oncol; 1995 May; 13(5):1096-102. PubMed ID: 7738615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.
    Hosing C; Saliba RM; McLaughlin P; Andersson B; Rodriguez MA; Fayad L; Cabanillas F; Champlin RE; Khouri IF
    Ann Oncol; 2003 May; 14(5):737-44. PubMed ID: 12702528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.